Home >> Research Area >>Neuroscience>>COX>> Rofecoxib

Rofecoxib

COX-2 inhibitor CAS# 162011-90-7

Rofecoxib

Catalog No. BCC4437----Order now to get a substantial discount!

Product Name & Size Price Stock
Rofecoxib: 5mg $6 In Stock
Rofecoxib: 10mg Please Inquire In Stock
Rofecoxib: 20mg Please Inquire Please Inquire
Rofecoxib: 50mg Please Inquire Please Inquire
Rofecoxib: 100mg Please Inquire Please Inquire
Rofecoxib: 200mg Please Inquire Please Inquire
Rofecoxib: 500mg Please Inquire Please Inquire
Rofecoxib: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Rofecoxib

Number of papers citing our products

Chemical structure

Rofecoxib

3D structure

Chemical Properties of Rofecoxib

Cas No. 162011-90-7 SDF Download SDF
PubChem ID 5090 Appearance Powder
Formula C17H14O4S M.Wt 314.36
Type of Compound N/A Storage Desiccate at -20°C
Synonyms MK 966
Solubility DMSO : 33.33 mg/mL (106.02 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
SMILES CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
Standard InChIKey RZJQGNCSTQAWON-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Rofecoxib

DescriptionRofecoxib(MK 966) is a potent inhibitor of the COX-2-dependent production of PGE2 in human osteosarcoma cells (IC50= 26±10 nM) and Chinese hamster ovary cells expressing human COX-2 (IC50=18±7 nM). IC50 value: 26 nM (cell assay) Target: COX2 Rofecoxib is a synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. Rofecoxib was used as an anti-inflammatory analgesic which has now been withdrawn from the market because of its association with cardiovascular problems.

References:
[1]. Chan CC, Boyce S, Brideau C et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551 [2]. Hillson JL, Furst DE. Rofecoxib. Expert Opin Pharmacother. 2000 Jul;1(5):1053-66. [3]. Weir MR, Sperling RS, Reicin A, Gertz BJ. et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003 Oct;146(4):591-604. [4]. Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin. 2007 Aug;23(8):1859-66.

Rofecoxib Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Rofecoxib Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Rofecoxib

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1811 mL 15.9053 mL 31.8107 mL 63.6213 mL 79.5267 mL
5 mM 0.6362 mL 3.1811 mL 6.3621 mL 12.7243 mL 15.9053 mL
10 mM 0.3181 mL 1.5905 mL 3.1811 mL 6.3621 mL 7.9527 mL
50 mM 0.0636 mL 0.3181 mL 0.6362 mL 1.2724 mL 1.5905 mL
100 mM 0.0318 mL 0.1591 mL 0.3181 mL 0.6362 mL 0.7953 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Rofecoxib

Rofecoxib is a potent and orally active inhibitor of cyclooxygenase (COX)-2 with IC50 value of 0.34μM [1].

Rofecoxib is an inhibitor of COX-2 and is developed as a new class of anti-inflammatory agents with improved gastrointestinal tolerability. It has been shown to be effective in the treatment of osteoarthritis. Rofecoxib potently inhibits COX-2 in cell-based assays with IC50 values ranging from 18nM to 46nM. In osteosarcoma cells, rofecoxib prevents the production of PGE2 with IC50 value of 26nM. Rofecoxib also shows effective inhibition of recombinant human COX-2 in stably transfected CHO cells with IC50 value of 18nM. Besides that, rofecoxib inhibits the activity of purified human COX-2 with IC50 value of 0.34μM in the in vitro assay with Genapol X-100 [1].

In the carrageenan-induced rat paw edema assay, administration of rofecoxib suppresses the edema response with ID50 value of 1.5mg/kg. And in rats with carrageenan-induced paw hyperalgesia, relieves the hyperalgesia with ID50 value of 1mg/kg [1].

References:
[1] Chan C C, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Journal of Pharmacology and Experimental Therapeutics, 1999, 290(2): 551-560.

Featured Products
New Products
 

References on Rofecoxib

Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression.[Pubmed:25472856]

Clin Exp Ophthalmol. 2015 Jul;43(5):458-65.

BACKGROUND: To explore the anti-angiogenesis mechanism of Rofecoxib and determine whether Rofecoxib can be a therapeutic agent for the prevention of retinal neovascularization using a model of retinopathy of prematurity (ROP). METHODS: ROP was induced by exposing mice to 75% oxygen from postnatal day 7 (P7 ) to P12 , then to room air from P12 to P17 . Sixteen mice were in each of the three groups: untreated ROP group as positive control, Rofecoxib-treated ROP group and the normal group (age-matched mice maintained in room air from birth to P17 as negative control). The localized expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) protein and mRNA in retinal blood vessels was assessed using immunohistochemistry, Western blot analysis and reverse transcription polymerase chain reaction. RESULTS: Mice in the Rofecoxib-treated group had a significantly reduced retinal neovascular tufts compared with those in the untreated ROP group. COX-2 and VEGF protein and mRNA expression levels were increased in the untreated ROP group, compared with the normal group. Rofecoxib decreased retinal angiogenesis by inhibiting COX-2 and VEGF expression. The expression levels of VEGF and COX-2 were positively correlated at mRNA and protein levels. CONCLUSIONS: COX-2 and VEGF expressions were both involved in the regulation of angiogenesis and had the same cellular localization. Expression of COX-2 correlated positively with VEGF in retinal neovascularization. Rofecoxib attenuated retinal angiogenesis by inhibiting the expression of COX-2 and VEGF mRNA and protein.

Rofecoxib-Induced Deleterious Effects Escape Detection by Organismal Performance Assays.[Pubmed:28042224]

J Pharm Negat Results. 2016;7(1):4-11.

BACKGROUND: Organismal Performance Assays (OPAs) are a unique toxicity quantification method used to assess the safety of potentially toxic compounds, such as pharmaceuticals. OPAs utilize genetically diverse wild mice (Mus musculus) housed in semi-natural enclosures wherein exposed individuals compete directly with controls for resources. Previously, OPAs have been successful in detecting adverse effects in mice that were exposed to paroxetine. Here, we further test OPAs utility in pharmaceutical safety assessment by testing OPAs with Rofecoxib, a drug with known adverse effects in humans. METHODS: We exposed mice to Rofecoxib (~37.5 mg/kg/day) during gestation and into early adulthood. Exposure ceased when individuals were released into enclosures. Five independent populations were established and Rofecoxib-exposed individuals (n = 58) competed directly with control individuals (n = 58) over 28 weeks. Organismal performance was determined by quantifying reproduction, survival and male competitive ability. RESULTS: In enclosures, Rofecoxib-exposed males had equal reproduction, survival and competitive ability. Rofecoxib-exposed females had equal survival compared to controls but experienced 40% higher reproductive output. CONCLUSIONS: The adverse health effects of Rofecoxib seen in humans escaped detection by OPAs, just as they had during traditional preclinical assays. These results may be explained by the exposure design (in enclosures, all animals were on the control diet), the relatively short duration of exposure, species differences, or because the health benefits of the drug negated the side effects. Similarly to numerous assays used in preclinical trials, OPAs cannot reveal all maladies, despite their demonstrated sensitivity in detecting cryptic toxicity from numerous exposures.

Crystal structure of rofecoxib bound to human cyclooxygenase-2.[Pubmed:27710942]

Acta Crystallogr F Struct Biol Commun. 2016 Oct 1;72(Pt 10):772-776.

Rofecoxib (Vioxx) was one of the first selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) to be approved for use in humans. Within five years after its release to the public, Vioxx was withdrawn from the market owing to the adverse cardiovascular effects of the drug. Despite the widespread knowledge of the development and withdrawal of Vioxx, relatively little is known at the molecular level about how the inhibitor binds to COX-2. Vioxx is unique in that the inhibitor contains a methyl sulfone moiety in place of the sulfonamide moiety found in other coxibs such as celecoxib and valdecoxib. Here, new crystallization conditions were identified that allowed the structural determination of human COX-2 in complex with Vioxx and the structure was subsequently determined to 2.7 A resolution. The crystal structure provides the first atomic level details of the binding of Vioxx to COX-2. As anticipated, Vioxx binds with its methyl sulfone moiety located in the side pocket of the cyclooxygenase channel, providing support for the isoform selectivity of this drug.

Molecular simulation study on concentration effects of rofecoxib with POPC bilayer.[Pubmed:27693948]

J Mol Graph Model. 2016 Nov;70:94-99.

The interactions between Rofecoxib and POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) bilayer were studied using all-atom molecular dynamics simulation method. Four POPC bilayer systems with different number of Rofecoxib molecules were constructed to simulate different drug concentration. The free energy of Rofecoxib passing across pure POPC bilayer has two minima (at z approximately 1.2nm or 1.6nm). As for the high concentration model, the minimum of the free energy profile slightly shifts to the bilayer center. Moreover, the energy change from bulk water to POPC bilayer increases while the central barrier to cross the hydrophobic core of bilayer slightly decreases, suggesting that increasing drug concentration makes it favorable for Rofecoxib to partition into the bilayer and easier to pass across bialyer center. Energy analysis show that the stabilization between the selected Rofecoxib and other pre-inserted Rofecoxib molecule is mainly due to van der Waals interaction energy. The predicted permeability of Rofecoxib in high concentration model slightly weakens as compared with low concentration model.

Description

Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

Keywords:

Rofecoxib,162011-90-7,MK 966,Natural Products,COX, buy Rofecoxib , Rofecoxib supplier , purchase Rofecoxib , Rofecoxib cost , Rofecoxib manufacturer , order Rofecoxib , high purity Rofecoxib

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: